Chinese drugmaker WuXi AppTec faces a December investor exodus as US restrictions tighten.

On 28 October, the US Department of Homeland Security banned imports from BGI Genomics, MGI Tech and BGI Group under forced-labour rules. Washington had already listed Chinese pharmaceuticals Novogene and WuXi as Chinese military companies in June, extending its crackdown across gene sequencing and drug manufacturing. A court suspended WuXi’s Pentagon designation in August, but the White House budget office can still list it separately. The next threat comes on 18 December, when the White House budget office must publish its list of “biotechnology companies of concern”. A listing would prevent federal agencies from buying from or funding companies that use WuXi’s services. WuXi is particularly exposed because US customers accounted for 77% of its US$4.28 billion revenue in the first half of 2026. Peer competitors Samsung Biologics and Lonza are poised to benefit from the fallout.